Back to search

Peptide record

TPDB02393

LL-III/8 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity standard

15 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB02393

Peptide_Name

LL-III/8

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb AVPpred-BWR APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 15-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

VNWKKILGKIIKVVK

FASTA

>TPDB02393|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Hemolysis;Toxicity|length=15
VNWKKILGKIIKVVK

Formula C86H152N22O17

Absent Amino Acids ARDCEQHMFPSTY

Common Amino Acids K

Mass 1766.29

PI 11.12

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +5

Boman Index 2.25

Hydrophobicity 0.373

Aliphatic Index 162.00

Half Life

Mammalian: 100 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 5500

Absorbance 280nm 311.39

Polar Residues 1

number

Amino Acid Distribution

A: 0 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 1 K: 5 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 3

Length

Formula

C86H152N22O17

Mass

1766.29

11.12

Net Charge

Boman Index

2.25

Hydrophobicity

0.373

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial and Antifungal

Origin

Lasioglossin III and its analogs

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 0.7 µM

Target

Target Organism B. subtilis

Source & Reference

Database Source dbAMP DRAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also kill

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 3.9 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhib

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 18.7 µM

Target

Target Organism Pseudomonas aeruginosa

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 1.4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP DRAMP

Other

Evidence Text

gainst B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the single cell yeast form to

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12±1 µM

Detail Source Activity Anticancer

Activity Measurement 12

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 6 Activity

Activity

Activity Raw

Not tested

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 9 µM

Detail Source Activity Anticancer

Activity Measurement 9 µM

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 8 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 0.7 µM

Target

Target Organism B. subtilis

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also kill

Evidence 9 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 3.9 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhib

Evidence 10 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 18.7 µM

Target

Target Organism Pseudomonas aeruginosa

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the

Evidence 11 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 1.4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source dbAMP DRAMP CAFPdb Antifungipept

Other

Evidence Text

gainst B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the single cell yeast form to

Evidence 12 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 0.7 µM

Target

Target Organism B. subtilis

Source & Reference

Database Source DRAMP

Other

Source Activity Label	Source Definition
Antiparasitic	DRAMP antiparasitic activity supported by activity records against parasitic targets.

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also kill

Evidence 13 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 3.9 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhib

Evidence 14 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 18.7 µM

Target

Target Organism Pseudomonas aeruginosa

Source & Reference

Database Source DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the

Evidence 15 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiparasitic

Activity Measurement 1.4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source DRAMP

Other

Evidence Text

gainst B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the single cell yeast form to

Evidence 16 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 0.7 µM

Target

Target Organism B. subtilis

Source & Reference

Database Source DRAMP

Other

Source Activity Label	Source Definition
Antiviral	DRAMP antiviral activity supported by activity records against viral targets.

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also kill

Evidence 17 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 3.9 µM

Target

Target Organism Staphylococcus aureus

Source & Reference

Database Source DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhib

Evidence 18 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 18.7 µM

Target

Target Organism Pseudomonas aeruginosa

Source & Reference

Database Source DRAMP

Other

Evidence Text

Active against B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the

Evidence 19 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antiviral

Activity Measurement 1.4 µM

Target

Target Organism Escherichia coli

Source & Reference

Database Source DRAMP

Other

Evidence Text

gainst B. subtilis (MIC 0.7 uM), S. aureus (MIC 3.9 uM), P. aeruginosa (MIC 18.7 uM), and E. coli (MIC 1.4 uM). Also killed C. albicans and inhibited its conversion from the single cell yeast form to

Evidence 20 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Hemolysis

Activity Measurement 220 µM

Hemolysis Raw

[Ref.19591185]LC50>220 µM against rat red blood cells

Target

RBC Target rat red blood cells

Source & Reference

Database Source Hemolytik APD_complete PD_Hemolysis

Source DRAMP4

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2099.

Other

Source Activity Label	Source Definition
Hemolysis	APD_complete APD-derived hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.

Evidence 21 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Hemolysis

Activity Measurement 200 µM

Hemolysis Raw

[Ref.19591185]LC50>200 µM against rat red blood cells

Target

RBC Target rat red blood cells

Source & Reference

Database Source Hemolytik APD_complete PD_Hemolysis

Source DRAMP4

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2114.

Evidence 22 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Hemolysis

Activity Measurement 79.3 µM

Hemolysis Raw

[Ref.19591185]LC50=79.3 µM against rat red blood cells

Target

RBC Target rat red blood cells

Source & Reference

Database Source Hemolytik APD_complete PD_Hemolysis

Source DRAMP4

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2115.

Evidence 23 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement >220 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | >220 | µM | target cell: Rat erythrocytes

Target

Target Cell Rat erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Evidence 24 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 15±4 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 15±4 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Target Cell Human umbilical vein endothelial cells HUVEC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 25 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 19±1 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 19±1 | µM | target cell: Rat intestinal epithelial cells IEC

Target

Target Cell Rat intestinal epithelial cells IEC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 26 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement >200 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | >200 | µM | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Effect of hydrocarbon stapling on the properties of ?-helical antimicrobial peptides isolated from the venom of hymenoptera. | Amino Acids | 2012

Evidence 27 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 29.6±3.0 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 29.6±3.0 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Target Cell Human umbilical vein endothelial cells HUVEC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Lipopeptisomes: Anticancer peptide-assembled particles for fusolytic oncotherapy. | Acta Biomater | 2018

Evidence 28 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement >200 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | >200 | µM | target cell: Rat erythrocytes

Target

Target Cell Rat erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Evidence 29 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 80 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 80 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Target Cell Human umbilical vein endothelial cells HUVEC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 30 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement >100 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | >100 | µM | target cell: Rat epithelial cells IEC-6, CRL-1592

Target

Target Cell Rat epithelial cells IEC-6, CRL-1592

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 31 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 79.3 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 79.3 | µM | target cell: Rat erythrocytes

Target

Target Cell Rat erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Evidence 32 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 30±2 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 30±2 | µM | target cell: Human umbilical vein endothelial cells HUVEC

Target

Target Cell Human umbilical vein endothelial cells HUVEC

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 33 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 18±3 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 18±3 | µM | target cell: Rat epithelial cells IEC-6, CRL-1592

Target

Target Cell Rat epithelial cells IEC-6, CRL-1592

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Toxicity study of antimicrobial peptides from wild bee venom and their analogs toward mammalian normal and cancer cells. | Peptides | 2012

Evidence 34 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement >100 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | >100 | µM | target cell: Rat erythrocytes

Target

Target Cell Rat erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

The antifungal effect of peptides from hymenoptera venom and their analogs. | Cent Eur J Biol | 2011

Evidence 35 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Toxicity

Activity Measurement 220 µM

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.19591185]LC50>220 µM against rat red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2099.

Evidence 36 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Toxicity

Activity Measurement 200 µM

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.19591185]LC50>200 µM against rat red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2114.

Evidence 37 Activity

Activity

Activity Endpoint LC50

Detail Source Activity Toxicity

Activity Measurement 79.3 µM

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.19591185]LC50=79.3 µM against rat red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2115.

Evidence 38 Hemolysis

Activity

Activity Measurement 220 µM

Activity Endpoint LC50

Hemolysis Raw

[Ref.19591185]LC50>220 µM against rat red blood cells

Detail Source Activity Hemolysis

Target

RBC Target rat red blood cells

Source & Reference

source APD_complete HemoPI PD_Hemolysis

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2099.

Source DRAMP4

Database Source APD_complete PD_Hemolysis

Other

Source Activity Label	Source Definition
Hemolysis	APD_complete APD-derived hemolytic peptide annotation.

Evidence 39 Hemolysis

Activity

Activity Measurement 200 µM

Activity Endpoint LC50

Hemolysis Raw

[Ref.19591185]LC50>200 µM against rat red blood cells

Detail Source Activity Hemolysis

Target

RBC Target rat red blood cells

Source & Reference

source APD_complete HemoPI PD_Hemolysis

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2114.

Source DRAMP4

Database Source APD_complete PD_Hemolysis

Evidence 40 Hemolysis

Activity

Activity Measurement 79.3 µM

Activity Endpoint LC50

Hemolysis Raw

[Ref.19591185]LC50=79.3 µM against rat red blood cells

Detail Source Activity Hemolysis

Target

RBC Target rat red blood cells

Source & Reference

source APD_complete HemoPI PD_Hemolysis

Reference

Chembiochem. 2009 Aug 17 10(12):2089-2115.

Source DRAMP4

Database Source APD_complete PD_Hemolysis